Skip to main content
. 2012 Dec 18;1(12):e62. doi: 10.1038/mtna.2012.54

Figure 3.

Figure 3

Treatment of mdx mouse muscle with B-PMO-mstn and B-PMO-dys induces dual myostatin and dystrophin exon skipping. Skipping of myostatin or dystrophin exons using B-PMOs following single or combined intramuscular injection (10 µg each) into the tibialis anterior (TA) of mdx mice. Mice were killed after 8 weeks and a nested RT-PCR was performed in treated and control-injected muscles. (a) Representative products of nested RT-PCR analysis of myostatin exon 2 skipping in muscles treated with excipient only (cont), B-PMO-mstn or the cocktail of B-PMO-mstn and B-PMO-dys. (b) Representative products of nested RT-PCR analysis of dystrophin exon 23 skipping in muscles treated with excipient only (cont), B-PMO-dys or a cocktail of B-PMO-mstn and B-PMO-dys. (c) Densitometric analyses of nested RT-PCR products for percentage of myostatin exon 2, or dystrophin exon 23 skipping in treated and control muscles after individual B-PMO-mstn or B-PMO-dys, or cocktail injection shows that coadministration of the two AOs has no detrimental effect on skipping efficiency. AO, antisense oligonucleotide; PMO, phosphorodiamidate morpholino oligomer; RT-PCR, reverse transcription-PCR.